ARS Pharmaceuticals (SPRY) Other Accumulated Expenses (2024 - 2026)

ARS Pharmaceuticals has disclosed Other Accumulated Expenses across 3 years of filings, most recently posting $592000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $592000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $592000.0 (changed N/A YoY), and the FY2025 annual result was $588000.0, up 1300.0% from the prior year.
• Other Accumulated Expenses came in at $592000.0 for Q1 2026 at ARS Pharmaceuticals, up from $588000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $3.1 million in Q3 2025 to a low of $42000.0 in Q4 2024.
• The 3-year median for Other Accumulated Expenses is $590000.0 (2025), against an average of $1.1 million.
• Peak annual rise in Other Accumulated Expenses reached 1300.0% in 2025, while the deepest fall reached 1300.0% in 2025.
• ARS Pharmaceuticals' Other Accumulated Expenses stood at $42000.0 in 2024, then soared by 1300.0% to $588000.0 in 2025, then grew by 0.68% to $592000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $592000.0 (Q1 2026), $588000.0 (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.